Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Nurexone Biologic: Jetzt diese wirklich einzigartige Chance ergreifen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
43 Leser
Artikel bewerten:
(2)

Global Biosimilars Market, 2022 - Market is Projected to Reach USD 28 Billion by 2020

DUBLIN, September 11, 2017 /PRNewswire/ --

The "Global Biosimilars Market-Growth, Trends & Forecasts 2017 - 2022" report has been added to Research and Markets' offering.

Research and Markets Logo

The Global Biosimilars Market was valued at USD 5237.0 currently and is projected to reach USD 28200.0 million by 2020, at a CAGR of 40.3% during the forecast period from 2015 to 2021.

The factors that are contributing to the growth of this market are the intended reductions in the healthcare expenditure, cost-effectiveness of biosimilar drugs, and the increasing number of off-patented drugs whose total sales in the year 2013 was USD 9.1 billion will expire in 2018 and 2016 in the EU and the US, respectively. Similarly, six such multi-billion drugs will expire in coming five years. Other than these, the rising demand for biosimilars is also another driving force for the biosimilars market.

However, there are factors that are restraining the growth of this market, such as the different regulatory frameworks and requirements in different countries and high manufacturing complexities, since the manufacturing of biosimilars requires sophisticated technologies. Although, small scale production is quite possible, but there is a risk involved in the scaling-up of the production. This brings forward the concern of operating on a large scale.

The major players of this market are Sandoz, Dr. Reddys, Teva Pharmaceuticals, Hospira, Bioton, Biocon, Sun-Ranbaxy, Zydus Cadila, Synthon, and Celltrion. This report offers comprehensive profiles of these companies composed of their business strategy for biosimilars.

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Market Overview

4. Porters Five Force Analysis

5. Market Segmentation

6. Biosimilars Market

7. Competitive Landscape

8. Company Profiles

  • Cipla
  • Dr Reddys
  • Teva pharmaceuticals
  • Sandoz
  • Hospira
  • Wockhardt
  • Bioton
  • Biocon
  • Sun-Ranbaxy
  • Reliance Life Sciences
  • Lg Life Sciences
  • 3SBio
  • Zydus Cadila
  • Actavis
  • Synthon
  • Celltrion
  • Mylan
  • Roche
  • Shanghai Fosun
  • Biosidus
  • Amgen

For more information about this report visit https://www.researchandmarkets.com/research/9jm93w/global


Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.